TLL-018 for chronic hives not helped by antihistamines
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug, TLL-018, for people with moderate-to-severe chronic hives (CSU) that don't respond well to standard antihistamines. The goal is to see if it works quickly to reduce itching and hives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had chronic hives (CSU) for at least 6 months.
- You still have itching and hives even though you take a second-generation antihistamine (like cetirizine or loratadine) at a standard dose.
- Your hives are moderate to severe, with a score of 16 or more on the UAS7 scale and an itch score of 8 or more in the week before the study starts.
- You are willing to continue taking your antihistamine during the study and fill out a daily symptom diary.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.
This trial tests a new medication called THB335 for people with chronic spontaneous urticaria (CSU), which causes hives and itching for months without a clear cause. The study will see if the drug can reduce hives and itching better than a placebo (a pill with no active medicine).
This study tests whether a bacterial lysate medicine (OM-85) combined with allergy medication can better control chronic hives in people whose regular allergy pills aren't working well enough. You'll be observed over time to see if this combination is safe and effective.
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.
Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.